NCT04762602View on ClinicalTrials.gov

A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations

PHASE1TerminatedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

February 28, 2021

Primary Completion Date

February 27, 2025

Study Completion Date

February 27, 2025

Conditions
Isocitrate Dehydrogenase Gene Mutation
Interventions
DRUG

HMPL-306

Administered orally QD in a 28-day continuous dosing treatment cycle

Trial Locations (11)

15232

UPMC Hillman Cancer, Pittsburgh

19107

Thomas Jefferson University, Philadelphia

28041

Hospital Universitario 12 de Octubre, Madrid

30322

Emory University, Atlanta

40536

University of Kentucky, Lexington

52242

University of Iowa, Iowa City

77030

Houston Methodist, Houston

The University of Texas MD Anderson Cancer Center, Houston

90403

Sarcoma Oncology Research Center, Santa Monica

08025

Hospital de la Santa creu i Sant Pau, Barcelona

08035

Hospital Universitari Vall d'Hebron, Barcelona

Sponsors

Lead Sponsor

Hutchmed
All Listed Sponsors
lead

Hutchmed

INDUSTRY

NCT04762602 - A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations | Biotech Hunter | Biotech Hunter